Uterus Transplant
Penn Medicine’s ongoing Uterus Transplantation for Uterine Factor Infertility (UNTIL) trial, which launched in 2017, is a potential treatment option for people with MRKH and other forms of UFI. The UNTIL trial is currently the only U.S. uterus transplant trial that is actively enrolling patients.
In November 2019, a woman enrolled in the UNTIL trial delivered the second baby in the nation to be born following transplantation of a uterus from a deceased donor.
Many other programs around the globe have focused on transplantation exclusively from living donors, and to date, there have been approximately 70 uterus transplants globally. However, Penn Medicine’s trial is one of few to explore donation from both living or deceased donors — an approach that has the potential to expand the pool of organs available for transplantation and allows investigators the opportunity to directly compare outcomes from the different types of donors.
There are surgical and non-surgical options to treat MRKH. Depending on your condition, you may benefit from one of the following:
Self-dilation
Self-dilation may allow you to create a vagina without surgery by using a small rod to expand your existing vagina over time.
Vaginoplasty
Surgical options are available if self-dilation doesn’t help you achieve your desired result.
You may have a vaginoplasty, during which a surgeon can create a functional vagina using a skin graft from your buttocks or a portion of your bowel. After a vaginoplasty, you will likely use a dilator, as well as artificial lubricant during intercourse, to help achieve and maintain a functional vagina.